The clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. The treatment plans for the treatment and management of the PF-ILD require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapted to timely regimens according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD-associated hepatitis C. The platform serves the China International Medical Service System, a team of domestically and internationally authoritative experts in the field of infectious respiratory digestive endocrine, to provide the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.